Intermediate Uveitis Treatment & Management
- Author: Robert H Janigian, Jr, MD; Chief Editor: Hampton Roy, Sr, MD more...
See the list below:
- Treatment of intermediate uveitis is undertaken to prevent permanent structural damage to vital ocular tissue, and, as a consequence, the method outlined by Kaplan is outdated.
- While mild asymptomatic vitreous cell may not require immediate treatment, any evidence of CME, neovascularization of the peripheral retina, extensive vasculitis, or significant vitreous cell requires treatment.
- Treatment is no longer based on an arbitrary level of vision. As with most forms of uveitis, corticosteroids are the mainstay of therapy.
- Topical therapy with prednisolone acetate 1% or prednisolone sodium phosphate 1% is only helpful in the treatment of the anterior segment inflammation. The intravitreal concentration of administered topically is too low to be efficacious in the face of moderate-to-severe vitritis, especially in the phakic patient.
- Periocular injections of corticosteroids are preferentially given in unilateral cases and occasionally in bilateral cases. Triamcinolone acetonide can be administered superotemporally into the sub-Tenon space or through the inferior eyelid into the retroseptal space. If the disease is not controlled after 2-3 injections given over an 8-week period, systemic prednisone should be considered. Some authorities advocate the use of a combination of betamethasone and depot methylprednisolone in an effort to achieve early onset and prolonged duration of action.
- Oral prednisone may be the preferred treatment in patients with bilateral intermediate uveitis or in cases resistant to topical or periocular steroids. A purified protein derivative (PPD) test is imperative prior to starting any patient on systemic corticosteroids if there are any risk factors for TB. Once the inflammation stabilizes, the oral dose is tapered according to disease activity. An H2 blocker (Tagamet or Zantac) or a proton pump inhibitor (Prilosec or Prevacid) can be prescribed adjunctively to oral steroids.
- Intravitreal triamcinolone acetonide injections have been used to treat CME. In a case series by Hogewind et al, of 33 eyes with intermediate or posterior uveitis and refractory CME, 50% improved greater than 2 lines at 3 months; but, by 12 months, the proportion of improved eyes declined to 40%.
- Several small case series have explored the use of somatostatin analogues (Octreotide) IM and intravitreal bevacizumab (Avastin) in patients with refractory uveitic CME.
- For recalcitrant cases with high corticosteroid requirements to control the inflammation, the surgical implantation of a device releasing fluocinolone acetonide in the vitreous can be considered (see Surgical Care).
- In the event that corticosteroids cannot control the intermediate uveitis or in those whose disease invariably flares when steroids are discontinued, immunosuppressive therapy often is attempted. Immunosuppression or immune-modulation is also used as part of the concept of steroid-sparing therapy in an effort to reduce the patient's requirement for systemic corticosteroids and, therefore, to diminish the adverse effects of systemic corticosteroid therapy.
- Cyclosporine, tacrolimus, azathioprine, and methotrexate are the most commonly used agents with documented efficacy in many uveitic conditions. Chlorambucil can be considered for intractable cases. They can be used concurrently with corticosteroids as steroid sparing agents or alone.
- Murphy et al prospectively evaluated the efficacy and the safety of cyclosporine and tacrolimus in patients with posterior and intermediate uveitis. The 2 agents did show a similar response rate (approximately 67%), but cyclosporine was associated with a higher incidence of adverse effects.
- The use of infliximab, an anti-tumor necrosis factor (anti-TNF) monoclonal antibody, has been shown to be effective in improving macular thickness and visual acuity in patients with uveitic refractory CME due to intermediate uveitis or other noninfectious uveitis. Initial successful reports by Markomichelakis et al were duplicated by Rajaraman et al in a pediatric population in which infliximab achieved reduction in intraocular inflammation with concurrent elimination or decrease in steroid requirements.[9, 10]
- Daclizumab, an interleukin-2 receptor blocking antibody, has been shown to be effective in noninfectious uveitis in a multicenter nonrandomized interventional case series. It allowed control of ocular inflammation with stability in visual acuity with reduction of concomitant immunosuppression by at least 50%. Daclizumab was withdrawn from the United States market because of diminished use and emergence of other effective therapies.
- Finally, interferon-beta (INF-beta), which has an established value in the treatment of MS, appears to have a positive effect in terms of visual acuity, CME, and aqueous and vitreous inflammation in intermediate uveitis associated with MS.
See the list below:
- Cryotherapy has been shown to be effective in treatment of intermediate uveitis. It may be used after periocular or systemic corticosteroid therapy failure and is often combined with a periocular steroid injection. Peribulbar anesthesia is required for this procedure.
- By ablating the peripheral retina with a transconjunctival approach, compromised vasculature can be destroyed, eliminating both the source for inflammatory mediators and the stimulus for neovascularization.
- The effect is noted after several weeks but may need to be repeated after 3-6 months.
- Devenyi et al reported that 90% of steroid-resistant eyes no longer required corticosteroid treatment after cryotherapy, and, in 78%, vitritis was eliminated.
- This surgical approach is not without complications including transient worsening of vitreous inflammation, decreased accommodative potential, cataract, hyphema, epiretinal membranes, and retinal detachment.
- Therefore, some authors advocate the use of cryotherapy only for patients with peripheral retinal neovascularization and a history of vitreous hemorrhage.
- Park and colleagues evaluated the use of peripheral scatter photocoagulation in 10 eyes with steroid-resistant pars planitis. Photocoagulation appeared to be as effective as cryotherapy in controlling intraocular inflammation and neovascularization of the vitreous base.
- Another surgical option for treating intermediate uveitis is pars plana vitrectomy.
- This modality is gaining popularity, because it theoretically reduces the antigen load and inflammatory mediators in the vitreous.
- Pars plana vitrectomy has been shown to decrease the intensity of the intraocular inflammation and reduce CME, but controlled clinical trials are lacking.
- In a published review of 44 interventional case series of pars plana vitrectomy for uveitis, the most common indication of pars plana vitrectomy was intermediate uveitis. This review by Becker et al grades pars plana vitrectomy as possibly relevant to the outcomes of improving vision and reducing inflammation and CME.
- Another small prospective study found that eyes randomized to pars plana vitrectomy/immunomodulatory therapy had improved uveitis compared with those given immunomodulatory therapy alone.
- Retinal detachment, cataract, and recurrent vitreous hemorrhage are known complications. Several authorities reserve the use of vitrectomy for patients with either dense vitreous debris with known complications of intermediate uveitis such as nonclearing vitreous hemorrhage or epiretinal membrane.
- Vitrectomy also may be indicated in patients who are steroid responders or those who cannot use/tolerate immunosuppressive therapy.
- In a retrospective analysis, pars plana vitrectomy was combined with cataract surgery in 22 of 43 eyes with intermediate uveitis; 40 of 43 eyes achieved a similar or better visual acuity after an average follow-up period of 45 months. In a small subset, immunosuppression could also be discontinued.
- For cases that require a high dose of systemic corticosteroids or frequent periocular injections to control flare-ups of the disease, the surgical implantation of a fluocinolone acetonide (Retisert) or dexamethasone (Ozurdex) implant can be considered. In a cohort of patients with recurrent posterior noninfectious uveitis, where the more severely affected eye was selected to receive a fluocinolone implant, the selected eyes showed a significant decrease in disease recurrences, from 51.4% to 6.1%, after 34 weeks of follow-up, with a moderate benefit in visual acuity as well. In addition, in a randomized trial, the 0.7-mg dexamethasone implant effectively reduced intraocular inflammation and improved visual acuity over a 6-month period.
- Many patients with intermediate uveitis develop cataract, either secondary to the disease process or due to corticosteroid treatment.
- Management of cataract in these patients is controversial.
- It is well established that maximal preoperative suppression of inflammation is imperative before cataract surgery. Younger patients should be cell free for 6 months prior to surgery, and older patients for at least 3 months, depending upon the judgment of the experienced operating surgeon.
- The controversy lies in whether these patients would benefit more from aphakic correction or intraocular lens (IOL) placement.
- Some authors report a poor visual outcome secondary to a postoperative escalation of inflammation and/or adherent debris onto the IOL, requiring multiple YAG laser procedures.
- Other investigators have found that select patients can enjoy a relatively uncomplicated postoperative course and improved visual acuity with pseudophakia.
- Although it was speculated that heparin surface-modified intraocular lenses would reduce postoperative debris collection and posterior synechiae, small prospective case series suggest that there is no statistical difference between heparin-coated IOLs and polymethyl methacrylate (PMMA) IOLs in terms of final visual acuity, lens deposits, posterior capsular opacities, or anterior/posterior synechiae.
- In a retrospective series of 86 patients (100 eyes) with pars planitis who underwent phacoemulsification, 91% had better visual acuity postoperatively and only 10% had a decrease in visual acuity as a result of reactivation of pars planitis or progression of CME. This study determined that acrylic IOL had a statistically significant lower incidence of posterior capsular opacification compared to PMMA IOLs.
A cost-effective, directed, patient-specific laboratory diagnostic evaluation is best directed by the informed ophthalmologist. This approach incorporates the demographics, history, and examination findings into a comprehensive, practical diagnostic approach to the patient with uveitis.
For any patient with uveitis, seek an internist for a general medical evaluation.
Input from a gastroenterologist, neurologist, or infectious disease specialist may be necessary, depending on physical findings or pertinent elements of the review of systems.
Consultation with an experienced chemotherapist is mandatory when using alkylating and cytotoxic agents.
Kimura SJ, Hogan MJ. Chronic Cyclitis. Arch of Ophthalmol. 1964. 71:193-201.
Raja SC, Jabs DA, Dunn JP, et al. Pars Planitis: Clinical Features and Class II HLA Associations. Ophthalmology. 1999. 106 (3):594-599. [Medline].
Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993 Jun. 100(6):818-24; discussion 825. [Medline].
Henderly DE, Haymond RS, Rao NA, et al. The significance of the pars plana exudate in pars planitis. Am J Ophthalmol. 1987 May 15. 103(5):669-71. [Medline].
Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral Patterns of Uveitis in a Tertiary Care Center. Archives of Ophthalmology. 1996. 114 (5):593-599. [Medline].
Kaplan HJ. Intermediate Uveitis (Pars Planitis, Chronic Cyclitis)- A Four Step Approach to Treatment. Saari KM, ed. Uveitis Update. Amsterdam: Exerpta Medica; 1984. 169-172.
Hogewind BF, Zijlstra C, Klevering BJ, et al. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol. 2008 May-Jun. 18(3):429-34. [Medline].
Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005 May. 123(5):634-41. [Medline].
Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004 Oct. 138(4):648-50. [Medline].
Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006 Feb. 113(2):308-14. [Medline].
Devenyi RG, Mieler WF, Lambrou FH, et al. Cryopexy of the vitreous base in the management of peripheral uveitis. Am J Ophthalmol. 1988 Aug 15. 106(2):135-8. [Medline].
Park SE, Mieler WF, Pulido JS. 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch Ophthalmol. 1995 Oct. 113(10):1277-80. [Medline].
Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005 Dec. 140(6):1096-105. [Medline].
Quinones K, Choi JY, Yilmaz T, Kafkala C, Letko E, Foster CS. Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: a prospective, randomized pilot study. Ocul Immunol Inflamm. 2010 Oct. 18(5):411-7. [Medline].
Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun. 113(6):1020-7. [Medline].
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May. 129(5):545-53. [Medline].
Thorne JE, Daniel E, Jabs DA, et al. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008 May. 145(5):841-6. [Medline].
Kalinina Ayuso V, Ten Cate HA, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. 2011 May. 95(5):646-51. [Medline].
Abu El-Asrar AM, Geboes K. An immunohistochemical study of the 'snowbank' in a case of pars planiti. Ocul Immunol Inflamm. 2002 Jun. 10(2):117-23. [Medline].
Androudi S, Ahmed M, Fiore T, et al. Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg. 2005 Mar. 31(3):472-8. [Medline].
Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005 Oct. 89(10):1254-7. [Medline].
Biswas J, Raghavendran SR, Vijaya R. Intermediate uveitis of pars planitis type in identical twins. Report of a case. Int Ophthalmol. 1998. 22(5):275-7. [Medline].
Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987 Feb 15. 103(2):234-5. [Medline].
Bonfioli AA, Damico FM, Curi AL, et al. Intermediate uveitis. Semin Ophthalmol. 2005 Jul-Sep. 20(3):147-54. [Medline].
Bora NS, Bora PS, Tandhasetti MT, et al. Molecular cloning, sequencing, and expression of the 36 kDa protein present in pars planitis. Sequence homology with yeast nucleopore complex protein. Invest Ophthalmol Vis Sci. 1996 Aug. 37(9):1877-83. [Medline].
Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001 Nov-Dec. 46(3):209-33. [Medline].
Brockhurst RJ, Schepens CL, Okamura ID. Uveitis II. Peripheral Uveitis: Clinical Descriptions, Complications and Differential Diagnosis. Am J Ophthalmol. 1960. 49:1257-1266.
Capone A Jr, Aaberg TM. Intermediate Uveitis. In: Albert, Jacobiec FA, eds. Principles and Practice of Ophthalmology. 1994. Philadelphia: WB Saunders:423-442.
Doro D, Manfre A, Deligianni V, et al. Combined 50- and 20-MHz frequency ultrasound imaging in intermediate uveitis. Am J Ophthalmol. 2006 May. 141(5):953-5. [Medline].
Duguid IG, Ford RL, Horgan SE, et al. Combined orbital floor betamethasone and depot methylprednisolone in uveitis. Ocul Immunol Inflamm. 2005 Feb. 13(1):19-24. [Medline].
Ganesh SK, Babu K, Biswas J. Phacoemulsification with intraocular lens implantation in cases of pars planitis. J Cataract Refract Surg. 2004 Oct. 30(10):2072-6. [Medline].
Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Experiment Ophthalmol. 2001 Apr. 29(2):81-4. [Medline].
Holland GN. The enigma of pars planitis, revisited. Am J Ophthalmol. 2006 Apr. 141(4):729-30. [Medline].
Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep. 140(3):509-16. [Medline].
Jain R, Ferrante P, Reddy GT, et al. Clinical features and visual outcome of intermediate uveitis in children. Clin Experiment Ophthalmol. 2005 Feb. 33(1):22-5. [Medline].
Kaplan HJ. Surgical Treatment of Intermediate Uveitis. Developments in Ophthalmology. 1992. 23:185-189. [Medline].
Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005 Jul. 89(7):806-8. [Medline].
Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002 Jan. 109(1):137-42. [Medline].
Murphy CC, Hughes EH, Frost NA, et al. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol. 2005 Sep. 89(9):1161-5. [Medline].
Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005 May. 112(5):764-70. [Medline].
Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice. 3rd ed. St. Louis: CV Mosby; 2004. 291-300.
Okada AA. Noninfectious uveitis: a scarcity of randomized clinical trials. Arch Ophthalmol. 2005 May. 123(5):682-3. [Medline].
Potter MJ, Myckatyn SO, Maberley AL, et al. Vitrectomy for pars planitis complicated by vitreous hemorrhage: visual outcome and long-term follow-up. Am J Ophthalmol. 2001 Apr. 131(4):514-5. [Medline].
Reinthal EK, Volker M, Freudenthaler N, et al. [Optical coherence tomography in the diagnosis and follow-up of patients with uveitic macular edema]. Ophthalmologe. 2004 Dec. 101(12):1181-8. [Medline].
Smith RE. Pars Planitis. Ryan SJ, ed. Retina. St. Louis: CV Mosby; 1973. Vol. 2: 637-646.
Smith RE, Godfrey WA, Kimura SJ. Chronic cyclitis. I. Course and visual prognosis. Trans Am Acad Ophthalmol Otolaryngol. 1973 Nov-Dec. 77(6):OP760-8. [Medline].
Smith RE, Nozik RA. Uveitis: A Clinical Approach to Diagnosis and Management. 2nd ed. Baltimore: Williams and Wilkins; 1989. 166-170.
Stanford MR, Vaughan RW, Kondeatis E, et al. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?. Br J Ophthalmol. 2005 Aug. 89(8):1013-6. [Medline].
Stavrou P, Baltatzis S, Letko E, et al. Pars plana vitrectomy in patients with intermediate uveitis. Ocul Immunol Inflamm. 2001 Sep. 9(3):141-51. [Medline].
Tabbara KF, Al-Kaff AS, Al-Rajhi AA, et al. Heparin Surface-Modified Intraocular Lenses in Patients with Inactive Uveitis or Diabetes. Ophthalmology. 1998. 105(5):843-845. [Medline].
Tessler HH, Fraber MD. Intraocular Lens Implantation Versus no Intraocular Lens Implantation in Patients with Chronic Iridocyclitis and Pars Planitis: A Randomized Prospective Study. Ophthalmology. 1993. 100 (8):1206-1209. [Medline].
Trittibach P, Koerner F, Sarra GM, et al. Vitrectomy for juvenile uveitis: prognostic factors for the long-term functional outcome. Eye. 2006 Feb. 20(2):184-90. [Medline].
Tugal-Tutkun I, Havrlikova K, Power WJ, et al. Changing patterns in uveitis of childhood. Ophthalmology. 1996 Mar. 103(3):375-83. [Medline].
Ozzello DJ, Palestine AG. Factors affecting therapeutic decisions in intermediate and posterior uveitis. Am J Ophthalmol. 2015 Feb. 159 (2):213-20.e3. [Medline].